Drug intelligence / Profile preview

Vacc-Ct1

Development stage: Unknown
Lead developer: Immunor
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

Vacc-Ct1 is an investigational therapeutic cancer vaccine developed by Immunor, specifically designed for the treatment of glioblastoma multiforme (GBM). The vaccine utilizes synthetic peptides to target Cytomegalovirus (CMV) antigens, which are frequently expressed in glioblastoma cells but are absent in healthy brain tissue. By presenting these viral antigens to the immune system, Vacc-Ct1 aims to stimulate a robust, tumor-specific T-cell mediated immune response to identify and eliminate cancer cells. The candidate is currently being evaluated in Phase 2 clinical trials as part of an immunotherapy approach to treat aggressive brain cancers.

Other names: CMV-antigen based vaccineImmunor CMV vaccine

Beyond the preview

Go deeper on Vacc-Ct1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacc-Ct1.

Explore the full profile